Every 10-Q that Zymeworks Inc. (ZYME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZYME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYME filings page.
Zymeworks Inc., a royalty‑focused biotechnology company, reported second‑quarter 2026 revenue of $4.6 million, down from prior‑year milestone‑driven levels, and a net loss of $45.0 million (six‑month loss $89.2 million). Operating expenses fell modestly, but collaboration revenue declined sharply.
Cash, cash equivalents and marketable securities totaled $322.5 million at June 30, 2026. Operating activities used $77.7 million of cash in the first half, offset by proceeds from a $250.0 million non‑recourse Royalty Pharma financing backed by 30% of future Ziihera royalties, recorded as a $252.6 million liability with a 10.7% effective interest rate.
The company repurchased 3.8 million shares for $91.1 million under its 2025 program and 2.0 million shares for $51.9 million under the 2026 program, reducing common shares outstanding to 71.4 million. It also agreed to acquire Theravance Biopharma for $17.00 in cash plus a CVR per share, to be financed with cash on hand and a committed $350.0 million debt facility, and highlighted potential Ziihera‑related regulatory milestones totaling up to $440.0 million for first‑line HER2‑positive GEA approvals.
Zymeworks Inc. reported a first-quarter 2026 net loss of $44.2 million, wider than the prior year, as collaboration revenue fell to $2.4 million from milestone-heavy Q1 2025. Operating expenses were stable at $49.5 million, with research and development of $34.5 million and general and administrative of $15.1 million.
Cash, cash equivalents and marketable securities rose to $403.8 million as of March 31, 2026, helped by a $250.0 million non‑recourse term loan obtained through monetizing 30% of future Ziihera royalties, recorded as a $246.5 million liability. The company continued its share repurchase strategy, buying back 3.2 million shares for $76.6 million in the quarter. Zymeworks highlights upcoming regulatory milestones for Ziihera in HER2‑positive gastroesophageal cancers and ongoing development of its ADC and multispecific antibody pipeline.
Zymeworks Inc. filed its Q3 2025 report, showing higher collaboration revenue and a narrower quarterly loss. Revenue from research and development collaborations was $27,614 for the quarter (vs. $16,000 a year ago), aided by partner milestones. Net loss was $19,602, translating to basic and diluted loss per share of $0.26.
For the nine months, collaboration revenue reached $103,450 (vs. $45,273), supported by payments from J&J ($25,000 Phase 3 start), BeOne ($20,000 milestone plus $18,334 deferred revenue recognized), BMS ($7,500 option), GSK ($14,000), and Daiichi Sankyo ($3,100). Operating expenses were $49,724 in Q3, with R&D of $35,578 and G&A of $14,146. Cash and cash equivalents were $64,834, with marketable securities of $234,526, and total assets of $397,269. The company repurchased 1,028,333 shares in Q3 for $15,691 and completed the net exercise of 5,086,480 pre‑funded warrants in June. Shares outstanding were 74,836,534 as of November 4, 2025.